Skip to main content
. 2018 Oct 19;32(2):280–291. doi: 10.1111/pcmr.12741

Figure 6.

Figure 6

The PAX3/BRN2 rheostat can be observed in tumours from patients. (a) RT‐qPCR analysis of PAX3, MITF, BRN2 and DUSP6 expression in A375 xenografts from mice treated with vemurafenib. Samples were from before treatment, 12 days on treatment and once tumours had progressed (Smith et al., 2016). (b) RT‐qPCR analysis of PAX3, MITF, BRN2, and DUSP6 expression in melanomas from patients treated with BRAF and MEK inhibitor. Samples were from before treatment, 2 weeks on treatment and once tumours had progressed (Smith et al., 2016)